12:00 AM
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Soligenix preclinical data

Soligenix said VeloThrax in combination with ThermoVax vaccine thermostabilization technology retained its potency and structural integrity when exposed to temperatures of up to 70 degrees Celsius for >=1 month. Additionally, VeloThrax in combination with ThermoVax and a secondary adjuvant led to rapid onset of...

Read the full 199 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >